Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Fluorodexamethasone
1. Flumetasone
2. 2135-17-3
3. Aniprime
4. Flucorticin
5. Flumethason
6. Anaprime
7. Methagon
8. Fluvet
9. Cortexilar
10. Flumetasona
11. Flumetasonum
12. Rs 2177
13. Flumetasone [inn]
14. Rs-2177
15. Flumethasone [usan]
16. 6alpha,9-difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
17. Nsc-54702
18. 6alpha,9alpha-difluoro-16alpha-methylprednisolone
19. U-10974
20. U-10,974
21. Lr3cd8sx89
22. Mls000028618
23. Chebi:34764
24. Flumetasone (inn)
25. (6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
26. Flumethasone (usan)
27. Smr000058690
28. Dsstox_cid_25365
29. Dsstox_rid_80828
30. Pregna-1,4-diene-3,20-dione,6,9-difluoro-11,17,21-trihydroxy-16-methyl-, (6a,11b,16a)-
31. Dsstox_gsid_45365
32. Flumethasonum
33. 6alpha-fluorodexamethasone
34. Mfcd00056464
35. Flucort (veterinary)
36. 6.alpha.-fluorodexamethasone
37. Nsc 54702
38. Flumetasonum [inn-latin]
39. 6-alpha-fluorodexamethasone
40. Flumetasona [inn-spanish]
41. Nsc54702
42. Ncgc00016604-01
43. Prestwick_229
44. Cas-2135-17-3
45. Einecs 218-370-9
46. Brn 5645455
47. Opera_id_1501
48. Prestwick0_000734
49. Prestwick1_000734
50. Prestwick2_000734
51. Prestwick3_000734
52. Flumethasone [mi]
53. Unii-lr3cd8sx89
54. 6alpha-fluoro-dexamethasone
55. Schembl4046
56. Bspbio_000688
57. Flumetasone [who-dd]
58. Mls001077306
59. Spbio_002627
60. Bpbio1_000758
61. 6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
62. Chembl1201392
63. Dtxsid2045365
64. Flumethasone [green Book]
65. Hms1570c10
66. Hms2097c10
67. Hms2234b11
68. Hms3714c10
69. (6s,8s,9r,10s,11s,13s,14s,16r,17r)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one
70. Amy38487
71. Hy-b1051
72. Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,17,21-trihydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-
73. Zinc3983936
74. Tox21_110518
75. S4088
76. Akos005256462
77. Akos015895435
78. Tox21_110518_1
79. Ac-2069
80. Ccg-220734
81. Cs-4573
82. Db00663
83. Flumethasone 100 Microg/ml In Methanol
84. Smp1_000127
85. Ncgc00021761-03
86. Ncgc00021761-05
87. Ncgc00021761-06
88. (6alpha,11beta,16alpha)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
89. As-12534
90. Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,17,21-trihydroxy-16alpha-methyl-(van)
91. Flumethasone 100 Microg/ml In Acetonitrile
92. F0945
93. D04208
94. Ec 218-370-9
95. T72075
96. 135f173
97. A855571
98. Sr-01000003144
99. Q-101387
100. Q4383636
101. Sr-01000003144-3
102. Brd-k61496577-001-03-8
103. Brd-k61496577-001-20-2
104. 6.alpha., 9.alpha.-difluoro-16.alpha.-methylprednisolone
105. (6?,11?,16?)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
106. (1r,2s,8s,10s,11s,13r,14r,15s,17s)-1,8-difluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0?,?.0??,??]heptadeca-3,6-dien-5-one
107. (6s,9r,10s,11s,13s,16r,17r)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxy-acetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one
108. 6.alpha., 9-difluoro-11.beta.,17,21-trihydroxy-16.alpha.-methylpregna-1, 4-diene-3,20-dione
109. 6.alpha.,9-difluoro-11.beta.,17,21-trihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione
110. 6alpha,9-difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione (flumetasone)
111. Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,17, 21-trihydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-
112. Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,17,21-trihydroxy-16.alpha.-methyl-
| Molecular Weight | 410.5 g/mol |
|---|---|
| Molecular Formula | C22H28F2O5 |
| XLogP3 | 1.9 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 2 |
| Exact Mass | 410.19048031 g/mol |
| Monoisotopic Mass | 410.19048031 g/mol |
| Topological Polar Surface Area | 94.8 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 839 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions
Flumethasone pivalate is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching.
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
D - Dermatologicals
D07 - Corticosteroids, dermatological preparations
D07A - Corticosteroids, plain
D07AB - Corticosteroids, moderately potent (group ii)
D07AB03 - Flumetasone
D - Dermatologicals
D07 - Corticosteroids, dermatological preparations
D07X - Corticosteroids, other combinations
D07XB - Corticosteroids, moderately potent, other combinations
D07XB01 - Flumetasone
Absorption
Minimal if applied topically
Primarily hepatic
Flumethasone is a glucocorticoid receptor agonist. This complex binds to the nucleus causing a variety of genetic activation and repressions. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flumethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
ABOUT THIS PAGE
A CAS-2135-17-3 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CAS-2135-17-3, including repackagers and relabelers. The FDA regulates CAS-2135-17-3 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CAS-2135-17-3 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CAS-2135-17-3 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CAS-2135-17-3 supplier is an individual or a company that provides CAS-2135-17-3 active pharmaceutical ingredient (API) or CAS-2135-17-3 finished formulations upon request. The CAS-2135-17-3 suppliers may include CAS-2135-17-3 API manufacturers, exporters, distributors and traders.
click here to find a list of CAS-2135-17-3 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CAS-2135-17-3 DMF (Drug Master File) is a document detailing the whole manufacturing process of CAS-2135-17-3 active pharmaceutical ingredient (API) in detail. Different forms of CAS-2135-17-3 DMFs exist exist since differing nations have different regulations, such as CAS-2135-17-3 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CAS-2135-17-3 DMF submitted to regulatory agencies in the US is known as a USDMF. CAS-2135-17-3 USDMF includes data on CAS-2135-17-3's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CAS-2135-17-3 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CAS-2135-17-3 suppliers with USDMF on PharmaCompass.
A CAS-2135-17-3 CEP of the European Pharmacopoeia monograph is often referred to as a CAS-2135-17-3 Certificate of Suitability (COS). The purpose of a CAS-2135-17-3 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of CAS-2135-17-3 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of CAS-2135-17-3 to their clients by showing that a CAS-2135-17-3 CEP has been issued for it. The manufacturer submits a CAS-2135-17-3 CEP (COS) as part of the market authorization procedure, and it takes on the role of a CAS-2135-17-3 CEP holder for the record. Additionally, the data presented in the CAS-2135-17-3 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the CAS-2135-17-3 DMF.
A CAS-2135-17-3 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. CAS-2135-17-3 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of CAS-2135-17-3 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CAS-2135-17-3 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CAS-2135-17-3 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CAS-2135-17-3 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CAS-2135-17-3 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CAS-2135-17-3 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CAS-2135-17-3 suppliers with NDC on PharmaCompass.
CAS-2135-17-3 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CAS-2135-17-3 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CAS-2135-17-3 GMP manufacturer or CAS-2135-17-3 GMP API supplier for your needs.
A CAS-2135-17-3 CoA (Certificate of Analysis) is a formal document that attests to CAS-2135-17-3's compliance with CAS-2135-17-3 specifications and serves as a tool for batch-level quality control.
CAS-2135-17-3 CoA mostly includes findings from lab analyses of a specific batch. For each CAS-2135-17-3 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CAS-2135-17-3 may be tested according to a variety of international standards, such as European Pharmacopoeia (CAS-2135-17-3 EP), CAS-2135-17-3 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CAS-2135-17-3 USP).
LOOKING FOR A SUPPLIER?
